



RECEIVED  
MAR 07 2002  
TECH CENTER 1600/2900  
PATENT  
1110-01801

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Takehiro YATOMI et al. Conf.:  
Appl. No.: 09/701,486 Group: 1647  
Filed: November 29, 2000 Examiner: L. SPECTOR  
For: PREVENTIVES/REMEDIES FOR AUTOIMMUNE  
DEMYELINATING DISEASE

LARGE ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents  
Washington, DC 20231

March 5, 2002

Sir:

Transmitted herewith is a Reply to Restriction/Election Requirement in the above-identified application.

- ☐ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- ☐ Petition for ( ) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ A check in the amount of \$0.00 is enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. A triplicate copy of this sheet is attached.

Appl. No. 09/701,486

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By *ma armstrong*  
Gerald M. Murphy, Jr., #28,977

MaryAnne Armstrong, PhD., #40,069

GMM/MAA/csp  
1110-0280P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

(Rev. 09/27/01)



RECEIVED  
PATENT  
MAR 07 2002  
TECH CENTER 1600/2900  
1116 0220P

#7B  
3/12/02

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: YATOMI et al.  
Appl. No.: 09/701,486 Group: 1647  
Filed: November 29, 2000 Examiner: L. Spector  
For: PREVENTIVES/REMEDIES FOR AUTOIMMUNE  
DEMYELINATING DISEASES

AMENDMENT AND RESPONSE TO ELECTION OF SPECIES

Assistant Commissioner for Patents  
Washington, DC 20231

March 5, 2002

Sir:

The following Amendments and Remarks are respectfully submitted in response to the Election of Species issued on February 5, 2002, in connection with the above-identified application.

IN THE SPECIFICATION

Please replace the paragraph beginning on page 6, line 21 with the following rewritten paragraph:

B1  
--Various studies have been recently conducted and reported for the relation between the multiple sclerosis and the apoptosis mediated by Fas/Fas ligand system. Sameer, D. et al. reported that they found the Fas ligand expressed in microglia cells and infiltrated T cells and the Fas expressed in oligodendrocytes, in the lesion of human multiple sclerosis (J. Exp. Med., vol. 184, pages 2361-2370, 1996). Kimberly A. et al. (J. Immunol., vol. 159, pages 3096-3099, 1997) and Hanspeter, W. et al. (J.